Accuray Announced That Results Of The Pace-B– Prostate Advances In Comparative Evidence – Trial Were Published In The New England Journal Of Medicine
Portfolio Pulse from Benzinga Newsdesk
Accuray's CyberKnife System, used in the PACE-B trial, demonstrated that stereotactic body radiation therapy (SBRT) offers comparable cancer control and tolerability to conventional radiotherapy, while significantly reducing treatment time for prostate cancer patients.
October 17, 2024 | 11:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Accuray's CyberKnife System was highlighted in the PACE-B trial for its effectiveness in treating prostate cancer with SBRT, offering comparable results to conventional methods but in a significantly shorter timeframe.
The publication of the PACE-B trial results in a prestigious journal like the New England Journal of Medicine is a strong endorsement of Accuray's CyberKnife System. The findings that SBRT offers comparable cancer control and tolerability to CRT, while reducing treatment time, could lead to increased adoption of the CyberKnife System. This positive development is likely to boost investor confidence and potentially drive up the stock price of Accuray in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90